Replimune Group News Today

In an indication with few treatment options for patients who are running out of time, Replimune Group Inc. revealed positive top-line results of its lead candidate, RP-1 (vusolimogene oderparepvec), in anti-PD-1-failed melanoma. Data from the phase I/II Ignyte study of RP-1 plus Opdivo (nivolumab, Bristol Myers Squibb Co.) showed the treatment hit the primary endpoint with a 12-month overall response rate of 33.6% and a median duration of response of more than 35 months.

Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) CEO Sushil Patel sold 20,194 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $6.47, for a total value of $130,655.18. Following the completion of the sale, the chief executive officer now owns […]

Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) CEO Sushil Patel sold 20,194 shares of the company’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $6.47, for a total value of $130,655.18. Following the completion of the sale, the chief executive officer now owns 212,014 shares […]

Replimune Group, Inc. (NASDAQ:REPL – Free Report) – Research analysts at Leerink Partnrs dropped their Q1 2025 earnings estimates for shares of Replimune Group in a research report issued on Thursday, May 16th. Leerink Partnrs analyst J. Chang now anticipates that the company will earn ($0.85) per share for the quarter, down from their previous […]

Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) COO Colin Love sold 17,615 shares of the stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $6.47, for a total transaction of $113,969.05. Following the transaction, the chief operating officer now directly owns 777,345 shares in the company, […]

Zura Bio (NASDAQ:ZURA – Get Free Report) and Replimune Group (NASDAQ:REPL – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, analyst recommendations, institutional ownership, dividends, valuation and profitability. Insider & Institutional Ownership 61.1% of Zura […]

Replimune Group (NASDAQ:REPL – Get Free Report) and Zura Bio (NASDAQ:ZURA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership. Risk & Volatility Replimune Group has a […]

(RTTNews) - Biotechnology company Replimune Group, Inc. (REPL) announced Tuesday changes to its executive leadership team designed to support the ...

Profund Advisors LLC lifted its position in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 19.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 31,557 shares of the company’s stock after purchasing an additional 5,045 shares during the quarter. Profund Advisors […]

In this article, we will take a look at the 12 best medical stocks to buy under $10.